← Back to Clinical Trials
Recruiting NCT06181929

NCT06181929 A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06181929
Status Recruiting
Phase
Sponsor Sang-Won Um
Condition Health Risk Behaviors
Study Type INTERVENTIONAL
Enrollment 200 participants
Start Date 2024-06-01
Primary Completion 2026-05-31

Eligibility & Interventions

Sex Female only
Min Age 45 Years
Max Age 74 Years
Study Type INTERVENTIONAL
Interventions
Low dose CT

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 200 participants in total. It began in 2024-06-01 with a primary completion date of 2026-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a single-arm prospective pilot study in a single institution. The target accrual is 200 participants of Korean, female sex, never smoker status, and family history of lung cancer. The study will aim to enroll 200 participants in two years.

Eligibility Criteria

Inclusion Criteria: 1. Age 45-74 years old 2. Korean female 3. Never smoker defined as a lifetime exposure of less than 100 cigarettes 4. Family history of lung cancer at first degree relatives (parents, siblings, or children) Exclusion Criteria: 1. Prior history of lung cancer. 2. Diagnosis of any cancer within the past five years 3. Participation in a cancer prevention trial. 4. Present symptoms suggestive of current lung cancer, including: unexplained weight loss of over 5 kilograms within the last 12 months or unexplained hemoptysis. 5. Medical or psychiatric condition precluding informed medical consent. 6. History of LDCT screening, chest CT, PET or PET/CT scan within 10 years

Contact & Investigator

Central Contact

Um Sang-Won, PhD

✉ sangwonum72@gmail.com

📞 82-2-3410-1645

Principal Investigator

Um Sang-Won, PhD

PRINCIPAL INVESTIGATOR

Samsung Medical Center

Frequently Asked Questions

Who can join the NCT06181929 clinical trial?

This trial is open to female participants only, aged 45 Years or older, up to 74 Years, studying Health Risk Behaviors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06181929 currently recruiting?

Yes, NCT06181929 is actively recruiting participants. Contact the research team at sangwonum72@gmail.com for enrollment information.

Where is the NCT06181929 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT06181929 clinical trial?

NCT06181929 is sponsored by Sang-Won Um. The principal investigator is Um Sang-Won, PhD at Samsung Medical Center. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology